Earnings Call Summary | VolitionRX(VNRX.US) Q1 2024 Earnings Conference
Earnings Call Summary | VolitionRX(VNRX.US) Q1 2024 Earnings Conference
The following is a summary of the VolitionRx Limited (VNRX) Q1 2024 Earnings Call Transcript:
以下是VolitionRX Limited（VNRX）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
VolitionRx reported Q1 revenue of approximately $170,000, a 15% increase compared to the same period last year, mainly generated from Nu.Q Vet operations.
The company finished the first quarter with cash/cash equivalents of approximately $11.8 million.
A goal to become cash flow neutral by 2025 has been set, through the reduction of expenditure by $10 million annually, revenue growth, and procuring non-dilutive funding and licensing payments from Nu.Q NET and Capture-PCR.
VolitionRx公佈的第一季度收入約爲17萬美元，與去年同期相比增長了15％，主要來自Nu.Q Vet的業務。
該公司在第一季度結束時現金/現金等價物約爲1180萬美元。
通過每年減少1000萬美元的支出、收入增長以及從Nu.Q NET和Capture-PCR獲得非稀釋性資金和許可付款，已經設定了到2025年實現現金流中立的目標。
Business Progress:
業務進展：
The company has made significant headway with the Nu.Q NET, Capture-PCR, and Nu.Q lung cancer technologies.
VolitionRx expects to complete data in two key areas, Nu.Q NET and Capture-PCR by next month, potentially leading to royalties and milestone payments within a year.
Progress continues in lung cancer studies, and successful results are soon to be released.
In veterinary operations, the rollout of the Nu.Q Vet canine test continues in the U.S., Europe, and Japan. Feedback has been positive.
Expansion into sepsis diagnosis shows significant progress, with plans to introduce a sepsis product under a licensing model.
The company intends to expand the application of their Capture-PCR test in the broader biopharma R&D market.
Preliminary discussions to extend the use of the Nu.Q Vet for monitoring purposes to veterinarians have begun.
Cost-saving measures are in place, including executive salary cuts, with a goal to reduce operating costs by $10 million in the next year.
該公司在Nu.Q NET、Capture-PCR和Nu.Q肺癌技術方面取得了重大進展。
VolitionRx預計將在下個月之前完成兩個關鍵領域的數據，即Nu.Q NET和Capture-PCR，這有可能在一年內獲得特許權使用費和里程碑式的支付。
肺癌研究繼續取得進展，不久將公佈成功結果。
在獸醫業務中，Nu.Q Vet犬類測試繼續在美國、歐洲和日本推出。反饋是積極的。
擴展到敗血症診斷領域取得了重大進展，計劃在許可模式下推出敗血症產品。
該公司打算擴大其捕獲聚合酶鏈反應測試在更廣泛的生物製藥研發市場的應用。
關於將Nu.Q Vet用於監測目的的使用範圍擴大到獸醫的初步討論已經開始。
已經採取了節省成本的措施，包括削減高管薪水，目標是在明年將運營成本降低1000萬美元。
More details: VolitionRX IR
更多詳情： VolitionRX 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。